Neurologic symptoms and neurodegeneration are important causes of morbidity and mortality in man. Although many pathogenic mechanisms could account for neurologic dysfunction, considerable interest has focused on a group of neurotoxins known as the 'excitotoxins'. Quinolinic acid (QUIN) is an excitotoxic L-tryptophan and kynurenine pathway metabolite that is an agonist of N-methyl-uaspartate (NMDA) receptors ( Figure 1) [l-31. The related metabolite, kynurenic acid (KYNA), is an antagonist of NMDA and other excitatory amino acid receptors that may protect against excitotoxins [4, 51. KYNA also induces neurologic dysfunction by interfering with excitatory amino acid neurotransmission [6] . Therefore, disturbances in the concentrations of QUIN and KYNA within the brain may have neurologic and neuropathologic consequences.
An understanding of the sources of kynurenine pathway metabolites in blood and central nervous system (CNS) is incomplete. One contemporary model has been derived from studies in normal rats. The liver is viewed as the predominant source of kynurenine pathway metabolites [7] , and has been suggested as the only source of QUIN in the body [S] . KYNA originates from L-kynurenine [9-111, which is synthesized in brain or enters the CNS from the blood [12- 
Kynurenine pathway metabolism following immune activation in man
Two simple studies have essentially defined the direction of our research program since 1987 on the effects of immune stimulation on the synthesis of QUIN and KYNA. Because the activity of indoleamine-2,3-dioxygenase (IDO), the first enzyme of the kynurenine pathway in extrahepatic tissues, is increased following administration of immune stimuli [19, 201, we predicted that I D 0 induction should be associated with accumulation of QUIN. We found that systemic administration of either endotoxin or pokeweed mitogen to mice resulted in an accumulation of QUIN in both the CNS and blood [21, 221. This observation led to the hypothesis that QUIN, as an NMDA receptor agonist, may be involved in the pathogenesis of seizures or neurodegeneration in inflammatory neurologic diseases [21] . To investigate whether immune stimulation in man was actually also associated with increases in QUIN, we first studied patients infected with the human immunodeficiency virus type-1 (HIV-l), an inflammatory neurologic disease [23] . The results showed that 10 non-demented acquired immunodeficiency syndrome (AIDS) patients had 2.9-fold elevations in cerebrospinal fluid (CSF) QUIN levels compared with nine control volunteers [241.
HIV-I infection and AIDS
After establishing the results described above, we discovered that CSF QUIN levels were elevated 3.5-fold in the very early stages of HIV-1 infection, whereas CSF KYNA levels were not increased significantly . CSF QUIN levels could be correlated with the severity of motor deficits in a task sensitive to basal ganglia lesions [25] . In laterstage patients with the AIDS dementia complex, opportunistic CNS conditions or aseptic meningitis, the increases in CSF QUIN averaged over 20-fold [26] (Figure 2) . Importantly, there were statistically significant correlations between the magnitude of the increases in CSF QUIN and quantitative measures of neuropsychologic deficits. Treatment with azidothymidine or anti-microbial therapy of opportunistic conditions appreciably reduced CSF QUIN levels, while neurologic status improved.
I993
Biochemical Society Transactions CSF QUIN levels were also elevated in HIV-1-infected children and the concentrations of QUIN also correlated with the severity of neurologic impairments [28] .
In the later-stage patients taken collectively, reductions in L-tryptophan accompanied proportional increases in 1,-kynurenine and QUIN in both serum and CSF [27, 291. Further, close inter-correlations were found between QUIN, KYNA and I,-kynurenine with both &-microglobulin and neopterin in CSF and serum [27, 29, 301 . These correlations support the hypotheses that the kynurenine pathway is activated in association with inflammation and is associated with induction of IDO. Notably, there were no relationships between the ratio of serum in CSF QUIN, L-kynurenine or KYNA:CSF albumin concentrations, which indicates that the increases in CSF QUIN, L-kynurenine or KYNA were not dependent on a breakdown of the blood-brain barrier [27, 291. Further, although serum QUIN exceeded CSF QUIN levels by 20- fold in control subjects, we found that 14.4% of the later-stage HIV-1 -infected patients had higher CSF than serum QUIN levels, an observation which supports intracerebral QUIN synthesis [2h].
Other inflammatory neurologic diseases
Because ID0 is induced by interferon-y, tumour necrosis factor, endotoxin and pokeweed mitogen, we predicted in 1988 that accumulations of QUIN within the CSF would occur in a broad spectrum of inflammatory neurologic diseases. We have found markedly increased concentrations of QUIN in both lumbar CSF and post mortem brain tissue of patients with inflammatory diseases (bacterial, viral, Studies in experimental animals have shown that KYNA can attenuate the excitotoxic effects of QUIN when present in higher molar concentrations [5] . The concentrations of QUIN in the CNS normally exceed those of KYNA. Further, we have found consistently that, following immune activation in man, non-human primates, gerbils and mice while CSF and brain tissue KYNA levels are increased along with increases in QUIN levels, the magnitude of the increases in QUIN is always larger than the increases in KYNA [27, 29, 31, [33] [34] [35] [36] [37] [38] . These results show that the balance between QUIN and KYNA favours excitotoxicity.
It is important to note that the increases in CSF QUIN and KYN levels in patients with inflammatory neurologic disease cannot be attributed simply to brain atrophy, dementia, motor disturb- ances, disturbances in food intake, non-specific stress, gliosis or siezures, as CSF QUIN and KYNA are not increased in patients with either Huntington's disease, Alzheimer's disease, seizures, depression, anorexia nervosa or bulimia nervosa [27, [39] [40] [41] [42] [43] [44] . CSF and brain tissue KYNA levels tend to be lower in patients with Huntington's disease [27, 451 or Alzheimer's disease [27] , although the significance of this reduction with respect to excitotoxicity remains to be established.
Animal models of inflammatory neurologic disease

Generalized immune activation
Macaques infected with either the simian immunodeficiency virus or the type-D retrovirus have proved to be excellent models of HIV-1 infection of systemic and CNS tissue. Our results to date show that increases in CSF and brain tissue QUIN concentrations also occur in retrovirus-infected macaques, and that such increases are largest in macaques with neurologic disease [27, 36, 37, 461.
The activity of I D 0 is also increased within the CNS in proportion to the concentrations of QUIN in the CSF and brain tissue [27, 471 . Induction of ID0 was also found in the lung, whereas the activity of hepatic tryptophan-2,3-dioxygenase was not affected.
In many of the inflammatory diseases studied, immune stimulation was present not only within the CNS, but also in systemic tissues. Consequently, it is difficult to differentiate CNS-restricted changes in kynurenine pathway metabolism from the contribution of systemic responses. We have proposed that it is highly likely that changes in systemic kynurenine pathway metabolism have a strong influence in the changes in QUIN and KYNA levels within the CNS, particularly in circumstances where immune activation is predominantly or exclusively systemic [27, 34, 381 . We have described a rodent model which can replicate the kynurenine pathway responses in both CNS and systemic tissues following sygemic immune activation that supports a contributory role for systemic kynurenine pathway responses in the CNS changes [20-22, 33, 341. However, the following two studies in experimental models have clearly established that the CNS is indeed capable of synthesizing QUIN and KYNA, independently of systemic contributions.
CNS-restricted immune activation
Poliovirus infection of rhesus macaques. 
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Therapeutic implications
Collectively, these observations support a role for QUIN in the pathogenesis of neurodegenerative changes in patients with a broad spectrum of inflammatory neurologic disease. The increases in QUIN and KYNA are attributable to increased activities of IDO, kynureninase, kynurenine 3-hydroxylase and 3-hydroxyanthranilate-3,4-dioxygenase, either within the CNS or systemic tissues. Both QUIN and KYNA may contribute to neurologic dysfunction by interfering with excitatory amino acid neurotransmission or NMDA receptors' function. Strategies to attenuate the receptor-mediated effects of QUIN, KYNA and other neuroactive kynurenines are potential avenues to therapy, although drugs which block NMDA receptors could conceivably accentuate neurologic deficits under some circumstances. In view of the role for interferon-y and other cytokines in I D 0 induction, drugs such as interferon-y antibodies or anti-inflammatory agents may also be useful therapies [ 341. Additional approaches include inhibitors of kynurenine pathway enzymes, such as 4-chloro-3-hydroxyanthranilic acid [ 501.
